Business Information
The group's principal activity is to discover, develop and market products to treat neurological disorders and cancers. The group researches to develop suitable drugs in treatment of neurological disorders like als, narcolepsy, peripheral neuropathies, head and spinal injury, alzheimer's and stroke. It also promotes and markets provigil for use by those suffering from excessive daytime sleepiness associated with narcolepsy; actiq (R), for the management of breakthrough cancer pain in opioid tolerant patients and the further development of gabitril (R), an adjunctive treatment for partial seizures associated with epilepsy. The group operates in the United States, France, the United Kingdom, Germany and Switzerland. On 12-Aug-2004, the group acquired cima labs inc.
|
|
Name |
Title
|
Email
|
| Frank Baldino | Chmn., CEO | N/A | | Carl Savini | Exec. VP, Chief Administrative Officer | N/A | | Jeffry Vaught | Exec. VP - Research, Development | N/A | | John Osborn | Exec. VP, General Counsel, Sec. | N/A | | Kevin Buchi | CFO, Exec. VP | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,764,069 | 144,816 | | 2005 | 1,211,892 | (174,954) | | 2004 | 1,015,425 | (73,813)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
